Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr 15;27(5):677-685.
doi: 10.1093/ibd/izaa251.

Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease

Mark T Osterman  1 , Kelli L VanDussen  2 , Ilyssa O Gordon  3 , Elisabeth M Davis  4 , Katherine Li  5 , Kate Simpson  6 , Matthew Ciorba  7 , Sarah C Glover  8 , Bincy Abraham  9 , Xueyan Guo  4 , Eric U Yee  10 , Felicia D Allard  10 , Jacqueline G Perrigoue  5 , Brian Claggett  11 , Bo Shen  12 , Thaddeus S Stappenbeck  6   13 , Julia J Liu  4
Affiliations
Randomized Controlled Trial

Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease

Mark T Osterman et al. Inflamm Bowel Dis. .

Abstract

Background: Therapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn's disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustekinumab (UST) and vedolizumab (VDZ) and its relationship to another biomarker, intestinal epithelial cell (IEC) pyroptosis, with respect to response to VDZ.

Method: Ileal biopsies from the UNITI-2 randomized controlled trial were analyzed for MVL as a predictor of clinical response to UST. In a 5-center academic retrospective cohort of CD patients, ileal MVL was analyzed to determine its predictive value for response to VDZ. Correlation between ileal MVL and IEC pyroptosis was determined, and the discriminant ability of the combination of 2 biomarkers to VDZ was examined.

Results: Clinical response in UST was significantly higher than placebo (65% vs 39%; P = 0.03), with patients with normal MVL (>1.7 µm) having the greatest therapeutic effect: 85% vs 20% (P = 0.02). For VDZ, clinical response with MVL of 1.35 to 1.55 µm was 82% vs 44% (<1.35 µm) and 40% (>1.55 µm; P = 0.038). There was no correlation between ileal MVL and IEC pyroptosis. The combination criteria of ileal pyroptosis <14 positive cells/1000 IECs or MVL of 1.35 to 1.55 µm could identify 84% of responders and 67% of nonresponders (P = 0.001).

Conclusion: Ileal MVL was predictive of response to UST and VDZ in prospective and retrospective CD cohorts. It was independent of ileal IEC pyroptosis, and combination of the 2 biomarkers enhanced the discriminate ability of responders from nonresponders to VDZ.

Keywords: biomarker; clinical remission; clinical response; endoscopic improvement; epithelial cells.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Ileal MVL is predictive of therapeutic response to ustekinumab in CD patients from UNITI-2. (A) Ileal MVL is an effect modifier of clinical response to ustekinumab (N = 95). (C) Clinical remission to ustekinumab stratified by pretreatment ileal MVL (N = 95). (D) Endoscopic response to ustekinumab stratified by pretreatment ileal MVL (N = 71).
FIGURE 2.
FIGURE 2.
Correlation between ileal MVL length and baseline disease activity indices. (A) Clinical disease activity by CDAI (N = 95). (B) Endoscopic disease activity by SES-CD total score (N = 95). (C) Endoscopic ileal disease activity by SES-CD ileal subscore (N = 67). (D) Histologic disease activity by global histology activity score (N = 95).
FIGURE 3.
FIGURE 3.
Ileal MVL is predictive of response to vedolizumab in CD patients from the multicenter retrospective cohort. (A) Clinical response as a function of ileal MVL (N = 64). (B) Correlation between ileal MVL and baseline clinical disease activity by HBI (N = 64). (C) Correlation between ileal MV length and baseline endoscopic disease activity by SES-CD (N = 58).
FIGURE 4.
FIGURE 4.
Ileal MVL and ileal IEC pyroptosis are independent and synergistic biomarkers for prediction of response to vedolizumab in CD. (A) Correlation between ileal MVL and ileal IEC pyroptosis on pretreatment biopsy samples (N = 64). (B) Improved discriminant ability for responders from nonresponders to vedolizumab (N = 64).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Targan SR, Hanauer SB, van Deventer SJ, et al. . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035. - PubMed
    1. Present DH, Rutgeerts P, Targan S, et al. . Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405. - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476. - PubMed
    1. Feagan BG, Rutgeerts P, Sands BE, et al. ; GEMINI 1 Study Group . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710. - PubMed
    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. ; GEMINI 2 Study Group . Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721. - PubMed

Publication types